Enthusiasm ran high at the inaugural UC San Diego Gene Therapy Initiative Symposium at the Roth Auditorium at the Sanford Consortium. Researchers, clinicians, and patient advocates gathered to share new discoveries in gene therapy—a rapidly evolving field that is reshaping modern medicine. CIRM served as a platinum sponsor of the event. Era of progress The … Continue reading UC San Diego Gene Therapy Initiative Symposium fueling progress in the field
CIRM Supports Groundbreaking Gene Therapy for AML and MDS
Image source: Canva The California Institute for Regenerative Medicine (CIRM) recently awarded $8 million to Rochelle Emery, MD, at Senti Bio to advance a clinical trial for a novel therapy targeting two forms of blood cancer, acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). About AML and MDS Both cancers have a five-year survival rate … Continue reading CIRM Supports Groundbreaking Gene Therapy for AML and MDS
Strategic Framework Impacts the Future of CIRM’s Research Funding
As the regenerative medicine field rapidly evolves, CIRM faces a key challenge: investing the remaining $3.86 billion in ways that deliver the greatest impact for Californians. To meet this challenge, CIRM launched the Strategic Allocation Framework (SAF) to prioritize resources and maximize the potential of regenerative medicine breakthroughs. What is the SAF? The SAF uses … Continue reading Strategic Framework Impacts the Future of CIRM’s Research Funding
CIRM Supports Innovative Gene Therapy for Rare Heart Disorder
Image Source: American Heart Association Journals The California Institute for Regenerative Medicine (CIRM) awarded $4 million to support a gene therapy for rare life-threatening genetic disorder. A rare heart disorder Known as desmoplakin gene variant arrhythmogenic cardiomyopathy (DSP ACM), the genetic disorder is a rare heart disorder. This preclinical award went to Deborah D. Ascheim, … Continue reading CIRM Supports Innovative Gene Therapy for Rare Heart Disorder
CIRM awards boost clinical trials for cancer, heart, and rare diseases
The California Institute for Regenerative Medicine (CIRM) has allocated $26 million to support clinical research targeting cancers, heart conditions, and rare diseases. This investment reinforces CIRM’s commitment to advancing innovative stem cell and gene therapy treatments through all stages of clinical development. This round of awards funds five projects within CIRM’s Clinical Program, which provides … Continue reading CIRM awards boost clinical trials for cancer, heart, and rare diseases
Turning Hope into Reality: How a Genetic Therapy Helped Connor
Photo credit: n-Lorem Connor Dalby is a 15‑year‑old who loves music and the beach, but his journey has been anything but ordinary. He was diagnosed with a rare mutation in the SCN2A gene, bringing significant challenges into his life. A few weeks after birth, he struggled with sleep and persistent stomach issues. By eight months … Continue reading Turning Hope into Reality: How a Genetic Therapy Helped Connor
Next Generation of Regenerative Medicine Scientists and the Golden Era of Biomedical Innovation
CIRM CEO and President, Jonathan 'JT' Thomas speaking in front of conference attendees. During the first-ever California Institute for Regenerative Medicine (CIRM) Trainee Networking Conference, more than 400 students and postdoctoral fellows from CIRM's Bridges, COMPASS, and Scholars programs gathered from different parts of California for a three-day event at the University of Southern California … Continue reading Next Generation of Regenerative Medicine Scientists and the Golden Era of Biomedical Innovation
Where Are They Now: Jake Javier
On the first day, of the 2024 CIRM Trainee Network Conference, Jake Javier took shared his experience as a clinical trial patient, as how he benefited from the innovative trial. The event done in partnership with the University of Southern California (USC) gave trainees from CIRM’s education and training programs an opportunity to engage with … Continue reading Where Are They Now: Jake Javier
A Conversation with CEO Cory Nicholas on Neurona Therapeutics’ Recent RMAT Designation
At the California Institute for Regenerative Medicine (CIRM), we enjoy highlighting achievements that come out of the research we support. We recently sat down with Cory Nicholas, PhD, CEO and Co-Founder of Neurona Therapeutics, to discuss an important milestone for the clinical-stage company. Neurona recently received the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation for … Continue reading A Conversation with CEO Cory Nicholas on Neurona Therapeutics’ Recent RMAT Designation
California high schoolers “ignite innovation” at 2024 SPARK conference
More than 100 student scientists from around California showcased their excitement for regenerative medicine and stem cell research at this year’s annual CIRM SPARK Conference in the sunny Inland Empire. Hosted by UC Riverside from Aug. 5-6 at the Riverside Convention Center, this year’s event showcased the extraordinary talent and enthusiasm of high school students … Continue reading California high schoolers “ignite innovation” at 2024 SPARK conference